Selective downregulation of the angiotensin II AT1-receptor subtype in failing human ventricular myocardium

Circulation

Volumn 95, Issue 5, 1997, Pages 1193-1200

  Asano, Koji ^a   Dutcher, Darrin L ^a   Port, J David ^a   Minobe, Wayne A ^a   Tremmel, Kelli D ^a   Roden, Robert L ^a   Bohlmeyer, Teresa J ^a   Bush, Erik W ^a   Jenkin, Matthew J ^a   Abraham, William T ^a   Raynolds, Mary V ^a   Zisman, Lawrence S ^a   Perryman, M Benjamin ^a   Bristow, Michael R ^a,b  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

angiotensin; polymerase chain reaction; radioisotopes; receptors

Indexed keywords

5 [2 [[2 HYDROXY 3 [4 (1 METHYL 4 TRIFLUOROMETHYL 2 IMIDAZOLYL)PHENOXY]PROPYL]AMINO]ETHOXY]SALICYLAMIDE; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN II [1 SARCOSINE 8 ISOLEUCINE]; BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; CYANOPINDOLOL I 125; IODINE 125; MESSENGER RNA;

ADULT; ARTICLE; CARDIOMYOPATHY; CLINICAL FEATURE; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; FEMALE; HEART MUSCLE FIBER MEMBRANE; HEART VENTRICLE FAILURE; HUMAN; HUMAN CELL; HUMAN TISSUE; LIGAND BINDING; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RECEPTOR DENSITY; RECEPTOR DOWN REGULATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

EID: 16944364094     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.95.5.1193     Document Type: Article

References (12)

1. Bristow MR, Ginsburg R, Minobe W, Cubicciotti RS, Sageman WS, Lurie K, Billingham ME, Harrison DC, Stinson EB. Decreased catecholamine sensitivity and ß-adrenergic receptor density in failing human hearts. N Engl J Med. 1982;307:205-211.
2. Bristow MR. Changes in myocardial and vascular receptors in heart failure. J Am Coll Cardiol 1993;22(suppl A):61A-71A.
3. Bristow MR, Minobe W, Rasmussen R, Larrabee P, Skerl L, Klein JW, Anderson FL, Murray J, Mestroni L, Karwande SV, Fowler M, Ginsburg R. β-Adrenergic neuroeffector abnormalities in the failing human heart are produced by local rather than systemic mechanisms. J Clin Invest. 1992;89:803-815.
4. Studer R, Reinecke H, Müller B, Holtz J, Just H, Drexler H. Increased angiotensin-1 converting enzyme gene expression in the failing human heart: quantification by competitive RNA polymerase chain reaction. J Clin Invest. 1994;94:301-310.
5. Hirsch AT, Talsness CE, Schunkert H, Paul M, Dzau VJ. Tissue-specific activation of cardiac angiotensin converting enzyme in experimental heart failure. Circ Res. 1991;69:475-482.
6. Urata H, Healy B, Stewart RW, Bumpus M, Husain A. Angiotensin II receptors in normal and failing human hearts. J Clin Endocrinol Metab. 1989;69:54-66.
7. Regitz-Zagrosek V, Friedel N, Heymann A, Bauer P, Neuß M, Rolfs A, Steffen C, Hildebrandt A, Hetzer R, Flecke E. Regulation, chamber localization, and subtype distribution of angiotensin II receptors in human hearts. Circulation. 1995;91:1461-1471.
8. Bumpus FM, Catt KJ, Chiu AT, DeGasparo M, Goodfriend T, Husain A, Peach MJ, Taylor DG, Timmermans PBMWM. Nomenclature for angiotensin receptors. Hypertension. 1991;17:720-723.
9. Timmermans PBMWM, Wong PC, Chieu AT, Herblin WF, Benfield P, Carini DJ, Lee RJ, Wexler RR, Saye JAM, Smith RD. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev. 1993;45:205-251.
10. Xiang JZ, Linz W, Becker H, Ganten D, Lang RE, Schölkens B, Unger T. Effects of converting enzyme inhibitors ramipril and enalapril on peptide action and sympathetic neurotransmission in the isolated heart. Eur J Pharmacol. 1985;113:215-223.
11. Bristow MR, Abraham WT. Anti-adrenergic effects of angiotensin converting enzyme inhibitors. Eur Heart J. 1995;16(suppl K):37-41.
12. Nagano M, Higaki J, Nakamura F, Higashimori K, Nagano N, Mikami H, Ogihara T. Role of cardiac angiotensin II in isoproterenol-induced left ventricular hypertrophy. Hypertension. 1992;19:708-712.